S. Cros

发表

Metabolism of ellipticine and derivatives and its involvement in the antitumor action of these drugs

D. Mansuy, C. Paoletti, P. Lesca, 1978 .

Platinum and palladium complexes of 3-methyl orotic acid: a route toward palladium complexes with good antitumor activity.

S. Wimmer, P. Castan, A. Beauchamp, 1990, Journal of inorganic biochemistry.

Electrodialysis desalination and reverse osmosis concentration of an industrial mussel cooking juice: Process impact on pollution reduction and on aroma quality

P. Jaouen, S. Cros, B. L. Ignot, 2006 .

Syntheses and in vitro evaluation of water-soluble "cationic metalloporphyrin-ellipticine" molecules having a high affinity for DNA.

B. Meunier, C. Auclair, G. Etemad-moghadam, 1991, Journal of medicinal chemistry.

Cytotoxic hybrid molecules ‘metalloporphyrin–ellipticine’ having a high affinity for DNA

B. Meunier, C. Auclair, G. Etemad-moghadam, 1989 .

Synthesis of water-soluble, cationic functionalized metalloporphyrins having a citotoxic activity

B. Meunier, C. Casas, G. Etemad-moghadam, 1990 .

Comparative cytotoxic and antitumoral effects of ellipticine derivatives on mouse L 1210 leukemia.

C. Paoletti, A. Moisand, N. Xuong, 1979, Chemico-biological interactions.

The biooxidation of cytotoxic ellipticine derivatives: a key to structure-activity relationship studies?

G. Grassy, B. Meunier, J. Bernadou, 1988, Molecular pharmacology.

Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides. Biological activities of the resulting adducts.

E. Guittet, B. Meunier, G. Pratviel, 1986, Journal of medicinal chemistry.

Inhibition of tumor cell growth in vitro and in vivo by 2-methyl 9-hydroxyellipticinium entrapped within phospholipid vesicles.

J. Tocanne, S. Cros, A. Sautereau, 1986, Biopharmaceutics & drug disposition.

THE ROLE OF PLATINUM-DNA LESIONS IN THE INHIBITION OF DNA

C. Cayrol, G. Villani, S. Cros, 1991 .

Antineoplastic activity of didemnin congeners: nordidemnin and modified chain analogues.

G. François, A. Aumelas, J. Poncet, 1991, Journal of medicinal chemistry.

Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.

C. Paoletti, F. Lavelle, S. Giorgi-Renault, 1991, Journal of medicinal chemistry.

Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.

M. Poupon, G. Lavielle, L. Kraus-Berthier, 1991, Cancer research.

The antitumor activity of some palladium(II) complexes with chelating ligands.

F. Wimmer, S. Wimmer, P. Castan, 1989, Anticancer research.

Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HCl.

P. Gros, C. Paoletti, C. Auclair, 1987, Cancer research.

Preparation and crystal structure of the hydroxo-bridged complex biscyclo-tri-μ-hydroxo-tris[(trans-1,2-diaminocyclohexane)platinum(II)] tris

J. Macquet, A. Beauchamp, S. Cros, 1985 .

LIMITS OF TOXIC AND TERATOGENIC TOLERANCE OF DIMETHYL SULFOXIDE

S. Cros, F. Caujolle, D. Caujolle, 1967, Annals of the New York Academy of Sciences.

Antitumor activity of 9-hydroxyellipticine (NSC 210717) ON L1210 mouse leukemia and the effect of route of injection.

C. Paoletti, J. Le Pecq, S. Cros, 1976, Cancer research.

Ellipticine and derivatives induce breakage of L1210 cells DNA in vitro.

C. Paoletti, C. Malvy, C. Auclair, 1979, Biochemical pharmacology.

In Vitro Oxidative Activation: A Model for the Cytotoxic Action of 9-Hydroxy Ellipticine Derivatives

M. Maftouh, B. Monsarrat, C. Paoletti, 1983 .

Some antitumor derivatives of ellipticine deprived of mutagenic properties.

C. Paoletti, P. Lesca, P. Lecointe, 1978, Chemico-biological interactions.

Toxicological and pharmacological studies on 9-hydroxy-ellipticine in mice.

C. Paoletti, P. Lecointe, S. Cros, 1975, Toxicology and applied pharmacology.

Interaction between ellipticine derivatives and circular supercoiled DNA as revealed by gel electrophoresis. Possible relationship with the mechanisms of cytotoxicity .

C. Malvy, S. Cros, 1986, Biochemical pharmacology.

Pharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane(isocitrato)platinum(II).

J. Armand, J. Macquet, S. Cros, 1984, Cancer research.

Antitumour activity of some cyclophosphazenes.

J. Labarre, J. Faucher, F. Sournies, 1979, European journal of cancer.

New designs in inorganic ring systems as anticancer drugs. Antitumor activity of the aziridino (ethylene-imino) derivatives (NPAz2)2NSOX with X = F, Az, Ph.

F. Sournies, S. Cros, J. C. van de Grampel, 1981, Cancer letters.

New designs in cyclophosphazenes as antitumour agents

J. Labarre, F. Sournies, S. Cros, 1980 .

Antitumour Activity Cyclophosphazenes of Some

J. Labarre, J. Faucher, S. Cros, 1979 .

Mutagenicity and cytotoxicity of five antitumor ellipticines in mammalian cells and their structure-activity relationships in Salmonella.

D. DeMarini, C. Paoletti, A. Hsie, 1983, Cancer research.

In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model

G. Atassi, N. Guilbaud, T. Dunn, 2004, Cancer Chemotherapy and Pharmacology.

Cytostatic trans-platinum(II) complexes.

N. Farrell, J. Souchard, F. Wimmer, 1989, Journal of medicinal chemistry.